Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...

Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...

We raise our fair value estimate for no-moat BeiGene to HKD 149 per share from HKD 132, based on better-than-expected Brukinsa sales in the last quarter and a faster ramp-up going forward.

Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160) has announced financial results and corporate updates from the fourth quarter and full year 2024. The company’s shares rose 7.5% to $278.38 on ...

Key Pipeline Highlights BeiGene’s portfolio strategy emphasizes rapid generation of early-stage clinical proof-of-concept data enabled by its speed- and cost-advantaged (“Fast to Proof of ...

SAN MATEO, Calif., February 25, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

SAN MATEO, Calif., February 25, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in ...

Beigene, Ltd. (NASDAQ:ONC – Get Free Report) shares reached a new 52-week high during trading on Friday .The company traded as high as $260.98 and last traded at $256.35, with a volume of 102450 ...

BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.